BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16086232)

  • 1. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.
    Chaffer CL; Dopheide B; McCulloch DR; Lee AB; Moseley JM; Thompson EW; Williams ED
    Clin Exp Metastasis; 2005; 22(2):115-25. PubMed ID: 16086232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
    Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
    Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
    Kim IY; Lee DH; Lee DK; Kim WJ; Kim MM; Morton RA; Lerner SP; Kim SJ
    Cancer Res; 2004 Oct; 64(20):7355-60. PubMed ID: 15492256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
    Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
    Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
    J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
    Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
    Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines.
    Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G
    Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13.
    Lafleur MA; Drew AF; de Sousa EL; Blick T; Bills M; Walker EC; Williams ED; Waltham M; Thompson EW
    Int J Cancer; 2005 Apr; 114(4):544-54. PubMed ID: 15551360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.
    Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED
    Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma.
    Gilles C; Polette M; Seiki M; Birembaut P; Thompson EW
    Lab Invest; 1997 May; 76(5):651-60. PubMed ID: 9166284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
    Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
    J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma.
    Yoshizaki T; Maruyama Y; Sato H; Furukawa M
    Int J Cancer; 2001 Jan; 95(1):44-50. PubMed ID: 11241310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated expression of membrane type 1 metalloproteinase (MT1-MMP) in reactive astrocytes following neurodegeneration in mouse central nervous system.
    Rathke-Hartlieb S; Budde P; Ewert S; Schlomann U; Staege MS; Jockusch H; Bartsch JW; Frey J
    FEBS Lett; 2000 Sep; 481(3):227-34. PubMed ID: 11007969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
    Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
    Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
    Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
    Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.
    Bernardo MM; Fridman R
    Biochem J; 2003 Sep; 374(Pt 3):739-45. PubMed ID: 12755684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.